WO2023017404A1

WO2023017404A1 - A device, a compound, for inhalation of an anti-viral agent

Info

Publication number: WO2023017404A1
Application number: PCT/IB2022/057398
Authority: WO
Inventors: Dr. M.sasthaa BEGUM
Original assignee: Begum Dr M Sasthaa
Priority date: 2021-08-13
Filing date: 2022-08-09
Publication date: 2023-02-16

Abstract

A device (100) for inhalation of an anti-viral agent comprising a first canister (102) containing pressurized ozone gas (106), a second canister (104) containing HFA along with 1% ethanol-water (108), actuators (110, 112) connected with the first canister (102) and the second canister (104), and a nozzle (114) connected with the actuators (110, 112). The actuators (110, 112), on pressing, is configured to open the first canister (102) and the second canister (104) and depressurize the ozone gas (106). The nozzle (114) is configured to form a solution (120) of the ozone gas (106) and the HFA with the 1% ethanol-water (108) and propel the solution (120). Further, the HFA is configured to propel ethanol-water (108) and allow a predetermined quantity of the solution (120) to come out of the actuators (110, 112) and the nozzle (114). The ethanol-water (108) is configured to enhance solubility of the ozone gas (106).

Description

A DEVICE, A COMPOUND, FOR INHALATION OF AN ANTI-VIRAL AGENT AND A METHOD OF COMPOSITION THEREOF

FIELD OF THE INVENTION

[001] Embodiment of the present invention relates to medical technology and more particularly to a device, a compound, for inhalation of an anti-viral agent and a method of composition thereof.

BACKGROUND OF THE INVENTION

[002] Virus has become a threat to the human life. It has resulted in enormous deaths throughout the world. Recently, the entire world has already faced the serious consequences of one such virus i.e. , Covid-19. There are many scientists, personnel in medical field and other fields trying to put their efforts in developing some treatment which will be very effective for curing or controlling the intensity of Covid-19 in patients. Though they have taken countless efforts, still the treatment to kill I remove Covid-19 virus from the human body remains a great challenge. There are a number of research being done in considering ozone for treatment of various diseases caused by different microbes. It was proved in small groups, the effectiveness of ozone in therapeutic action.

[003] At present Remdesivir is used for the treatment of corona virus. It is an investigational drug being studied to treat coronavirus infection. Though there is limited information known about the safety and effectiveness of using remdesivir to treat COVID- 19, now been used widely for the treatment. Some study results show that remdesivir may help some patients get better sooner. The information in this document reflects preliminary and emerging data, which is evolving and subject to reassessment. Remdesivir given by injection into a vein usually once daily for 5 to 10 days. It is infused over a period ranging from 30 minutes to 2 hours. [004] Side effects: An infusion reaction may occur with remdesivir with symptoms such as low blood pressure, nausea, vomiting, sweating, and shivering. The healthcare professional should monitor for side effects during remdesivir treatment. In the case of a serious allergic reactions, symptoms may include rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. Some medical conditions taken into consideration during remdesivir treatment include kidney disease, liver disease. Information is limited and it is unknown at this time how safe and effective remdesivir is for senior citizen, children, or pregnant women, or if it affects nursing infants.

[005] Therefore, there is a need a device, a compound a method of composition for inhalation of an anti-viral agent. That can overcome the draw backs of the above- mentioned solution.

OBJECT OF THE INVENTION

[006] An object of the present invention is to provide a device for inhalation of an antiviral agent.

[007] Another object of the present invention is to provide a method of composition of compound for inhalation of an anti-viral agent.

[008] Yet another object of the present invention is to provide a compound for inhalation of an anti-viral agent.

[009] Yet another object of the present invention is to reduce risks related to viral infection treatment.

[010] Yet another object of the present invention is to increase effectiveness of cure to treat viral infection.

SUMMARY OF THE INVENTION

[011] This summary is provided to introduce a selection of concepts, in a simple manner, which is further described in the detailed description of the invention. This summary is neither intended to identify key or essential inventive concepts of the subject matter, nor to determine the scope of the invention.

[012] According to first aspect of the present invention, there is provided a device for inhalation of an anti-viral agent. The device comprises a first canister containing pressurized ozone gas, a second canister containing hydro fluoro alkane (HFA) along with 1 % ethanol-water, one or more actuators connected with the first canister and the second canister, and a nozzle connected with the actuator. Further, the actuator, on pressing, is configured to open the first canister and the second canister and depressurize the ozone gas. Furthermore, the nozzle is configured to receive and form a solution by mixing the depressurized ozone gas and the HFA along with the 1 % ethanol-water and propel the solution through a mouth to lungs of a user. In addition, the HFA is configured to propel ethanol-water and allow a predetermined quantity of the solution to come out of the actuator and the nozzle. Additionally, the ethanol-water is configured to enhance solubility of the ozone gas.

[013] In accordance with an embodiment of the present invention, the HFA used is HFA134a.

[014] In accordance with an embodiment of the present invention, the actuator comprises one or more aerosol valves.

[015] In accordance with an embodiment of the present invention, the predetermined quantity of the solution comprises 1 microgram (mcg) of the ozone gas, 1 ml of the 1 % ethanol-water, and quantum satis (q.s) HFA134a.

[016] In accordance with an embodiment of the present invention, the pressurized ozone gas is contained at a pressure of 2 bar.

[017] In accordance with an embodiment of the present invention, the solution is ejected from the nozzle at a velocity of 30m/s.

[018] According to second aspect of the present invention, there is provided a compound of anti-viral agent. The compound comprises ozone gas, hydro fluoro alkane (HFA), and 1 % ethanol-water. Further, the 1 % ethanol-water is configured to enhance solubility of the ozone gas.

[019] In accordance with an embodiment of the present invention, the ozone gas is polar and thereby dissolves in the ethanol-water.

[020] In accordance with an embodiment of the present invention, a dose of the compound comprises 1 microgram (mcg) of the ozone gas, 1 ml of the 1 % ethanol-water, and quantum satis (q.s) HFA134a. [021] According to third aspect of the present invention, there is provided a method of composition of anti-viral agent, the method comprises steps of storing ozone gas at a predetermined pressure, depressurizing the stored ozone gas, and mixing hydro fluoro alkane (HFA) along with 1 % ethanol-waterwith the depressurized ozone gas. Further, the 1 % ethanol-water is configured to enhance solubility of the ozone gas.

BRIEF DESCRIPTION OF THE DRAWINGS

[022] So that the manner in which the above recited features of the present invention can be understood in detail, a more particular to the description of the invention, briefly summarized above, may be had by reference to embodiments, some of which are illustrated in the appended drawings. It is to be noted, however, that the appended drawings illustrate only typical embodiments of this invention and are therefore not to be considered limiting of its scope, the invention may admit to other equally effective embodiments.

[023] These and other features, benefits and advantages of the present invention will become apparent by reference to the following text figure, with like reference numbers referring to like structures across the views, wherein:

Fig. 1 illustrates a device for inhalation of an anti-viral agent, in accordance with an embodiment of the present invention; and

Fig.2 illustrates working of the device as illustrated in figure 1 , in accordance with an embodiment of the present invention.

DETAILED DESCRIPTION OF THE DRAWINGS

[024] While the present invention is described herein by way of example using embodiments, those skilled in the art will recognize that the invention is not limited to the embodiments of drawing or drawings described and are not intended to represent the scale of the various components. Further, some components that may form a part of the invention may not be illustrated in certain figures, for ease of illustration, and such omissions do not limit the embodiments outlined in any way. It should be understood that the drawings and detailed description thereto are not intended to limit the invention to the particular form disclosed, but on the contrary, the invention is to cover all modification/s, equivalent/s and alternative/s falling within the scope of the present invention as defined by the appended claim. The headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description or the claim. As used throughout this description, the word "may" is used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning must).

[025] Further, the words "a" or "an" means "at least one” unless otherwise mentioned. Furthermore, the terminology and phraseology used herein is solely used for descriptive purposes and should not be construed as limiting in scope. Language such as "including", "comprising", "having", "containing", or "involving" and variations thereof, is intended to be broad and encompass the subject matter listed thereafter, equivalents, and additional subject matter not recited, and is not intended to exclude other additives, components, integers or steps. Likewise, the term "comprising" is considered synonymous with the terms "including" or "containing" for applicable legal purposes. Any discussion of documents, acts, materials, devices, articles and the likes are included in the specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention.

[026] In this disclosure, whenever an element or a group of elements is preceded with the transitional phrase “comprising”, it is understood that we also contemplate the same composition, element or group of elements with transitional phrases “consisting of”, “consisting”, “selected from the group of consisting of”, “including”, or “is” preceding the recitation of the composition, element or group of elements and vice versa.

[027] This invention described herein may be embodied in many different forms and should not be construed as limited to the embodiment set forth herein. Rather, the embodiment is provided so that this disclosure will be thorough and complete and will fully convey the scope of the invention to those skilled in the art. In the following description, numeric values and ranges are provided for various aspects of the implementations described. These values and ranges are to be treated as examples only and are not intended to limit the scope of the claims. In addition, a number of materials are identified as suitable for various facets of the implementations. These materials are to be treated as exemplary and are not intended to limit the scope of the invention. [028] The present invention takes into account the three major positive areas of ozone: 1 . Germicidal action of ozone. 2. The by-product of ozone is oxygen which enhances the metabolic rate in human being. 3. The post effect of this therapy is negligible compared to the post effects of medicines like steroids.

[029] Figure 1 illustrates a device (100) for inhalation of an anti-viral agent, in accordance with an embodiment of the present invention. As shown in figure 1 , the device (100) comprises a first canister (102), a second canister (104), one or more actuators (110, 112) connected with the first canister (102) and the second canister (104), and a nozzle (114) connected with the one or more actuators (110, 112). Further, as shown in figure 1 , the one or more actuators (110, 112) comprises one or more aerosol valves (116, 118). The first canister (102) and the second canister (104) are made of, non-reactive materials such as, but not limited to, glass, fiber glass, PVC, PMMA, plastic, alloys, aluminium alloy, titanium, gold plated aluminium, steel, titanium, ceramic etc.

[030] As shown in figure 1 , the first canister (102) containing pressurized ozone gas (106). The pressurized ozone gas (106) may be contained at a pressure of range 0.5 bar to 10 bars. The second canister (104) containing hydro fluoro alkane (HFA) along with 0.1 % to 3% ethanol-water (108). In accordance with an embodiment of the present invention, the HFA used is may be, but not limited to, HFA134a. Further, as shown in figure 1 , the one or more actuators (110, 112) connected with the first canister (102) and the second canister (104).

[031] Further, figure 2 illustrates working of the device as illustrated in figure 1 , in accordance with an embodiment of the present invention. As shown in figure 2, the one or more actuators (110, 112), on pressing the first canister (102) is configured to open the first canister (102) and depressurize the ozone gas (106). The one or more actuators (110, 112), on pressing the second canister (104), is configured to diffuse the HFA along with the 1 % ethanol-water (108).

[032] In accordance with an embodiment of the present invention the nozzle (114) connected with the one or more actuators (110, 112) is configured to receive and form a solution (120) by mixing the depressurized ozone gas (106) and the HFA along with the 1 % ethanol-water (108). the solution (120) comprises ozone gas (106), hydro fluoro alkane (HFA), and 1 % ethanol-water (108). The 1 % ethanol-water (108) is adapted to enhance solubility of the ozone gas (106). The ozone gas (106) is polar and presence of ethanol-water (108) increases the solubility of the ozone gas.

Mechanism:

Ozone decomposes partly into OH* radicals. These radicals act as initiator for the decay of ozone.

The radicals that are produced in the second reaction can introduce other reactions with ozone causing more OH* radicals to be formed.

[033] Further, in accordance with an embodiment of the present invention, the nozzle (114) is configured to propel the solution (120) through a mouth to lungs of a user. The HFA is adapted to propel ethanol-water (108) and allow a predetermined quantity of the solution (120) to come out of the one or more actuators (110, 112) and the nozzle (114). The predetermined quantity of the solution (120) comprises 1 microgram (mcg) of the ozone gas (106), 1 ml of the 1 % ethanol-water (108), and quantum satis (q.s) HFA134a. In accordance with an embodiment of the present invention, the solution (120) is ejected from the nozzle (114) at a velocity of range 2m/s to 100m/s.

[034] Ozone in dissolved form (distilled water) at specified concentration, taken in the form of inhaler using the device (100), through the mouth directly enter the lungs where it carries out the germicidal action and also provide sufficient oxygen for the functioning. The best germicidal function of ozone is made use of and is made to decompose. Ozone in solution (120) is a powerful germicide. Viruses in water in human body are more susceptible to ozone inactivation and short contact time about 1min or little more than that is sufficient to inactivate 99% of them. Ozone acts on protein part (outer cover) of Corona virus and denatures it. Due to this, Corona virus is deactivated I killed immediately.

[035] An aqueous solution of ozone prepared in distilled water proved to have much shorter half-life compared to tap water. Ozone with concentration merely 0.1 ppm (1 mg per lit) can be made to enter into the lungs through breathing. The concentration can be changed/modified according to the requirement and human response. This action is done using propellant the HFA. HFA is not environmentally inert as it is a greenhouse gas, but it does not affect the ozone layer.

[036] As the half-life of ozone in water at human body temperature of around 35 to 37°C, within 20 min, the entire ozone after killing the corona virus decomposes and release oxygen which activates the metabolic rate in human system.

[037] The user administers with the solution (120) is kept under constant medical supervision and immediately given other medical support as per the requirement. The possible effects may be irritation in throat or slight breathing difficulty which can be treated effectively. After administration of the solution (120), the effectiveness is constantly checked and the sign of any improvement in the patient is monitored and recorded. On confirming the positive improvement shown by the patient, in killing the corona virus, the next dose can be administered.

[038] The present invention provides a number of advantages. Firstly, this kind of inhalation will be very effective, and it can, possibly kill the corona virus by deactivating it. The present invention helps in reducing the intake of a lot of steroidal medicines. Saves the most valuable human life. The present invention reduces the post effects generally caused by intake of other medicines. It enhances the metabolic rate of human system, by providing oxygen. The present invention may decrease the use of oxygen ventilators/ oxygen cylinders which has become a challenging issue in current situation. It is very cost effective which can be bought by any single individual in India. The present invention is very effective against Corona Virus, it may not only save the valuable human life but also gradually eradicate this deadly virus from the country. This may also help in turn to save our country’s economic drop due to lock down and other measures taken for saving the human lives.

[039] Various modifications to these embodiments are apparent to those skilled in the art from the description and the accompanying drawings. The principles associated with the various embodiments described herein may be applied to other embodiments. Therefore, the description is not intended to be limited to the embodiments shown along with the accompanying drawings but is to be provided broadest scope consistent with the principles and the novel and inventive features disclosed or suggested herein. Accordingly, the invention is anticipated to hold on to all other such alternatives, modifications, and variations that fall within the scope of the present invention and the appended claims.

Claims

CLAIMS:

1. A device (100) for inhalation of an anti-viral agent, the device (100) comprising: a first canister (102) containing pressurized ozone gas (106); a second canister (104) containing hydro fluoro alkane (HFA) along with 1 % ethanol-water (108); one or more actuators (110, 1 12) connected with the first canister (102) and the second canister (104); and a nozzle (1 14) connected with the one or more actuators (1 10, 1 12); wherein the one or more actuators (1 10, 1 12), on pressing, is configured to: open the first canister (102) and the second canister (104); and depressurize the ozone gas (106); wherein the nozzle (1 14) is configured to receive and form a solution (120) by mixing the depressurized ozone gas (106) and the HFA along with the 1 % ethanol-water (108); and propel the solution (120) through a mouth to lungs of a user; wherein the HFA is configured to propel ethanol-water (108) and allow a predetermined quantity of the solution (120) to come out of the one or more actuators (1 10, 1 12) and the nozzle (1 14); and wherein the ethanol-water (108) is configured to enhance solubility of the ozone gas (106).

2. The device (100) as claimed in claim 1 , wherein the HFA used is HFA134a.

3. The device (100) as claimed in claim 1 , wherein the one or more actuators (110, 1 12) comprises one or more aerosol valves (116, 1 18). The device (100) as claimed in claim 1 , wherein the predetermined quantity of the solution (120) comprising:

1 microgram (mcg) of the ozone gas (106);

1 ml of the 1% ethanol-water (108); and quantum satis (q.s) HFA134a (108). The device (100) as claimed in claim 1 , wherein the pressurized ozone gas (106) is contained at a pressure of 2 bar. The device (100) as claimed in claim 1 , wherein the solution (120) is ejected from the nozzle (114) at a velocity of 30m/s. A compound of anti-viral agent, the compound comprising: ozone gas (106); hydro fluoro alkane (HFA) (108); and

1% ethanol-water (108); wherein the 1% ethanol-water (108) is configured to enhance solubility of the ozone gas (106). The compound as claimed in claim 7, wherein the ozone gas (106) is polar and thereby dissolves in the ethanol-water (108). The compound as claimed in claim 7, wherein a dose of the compound comprising:

1 microgram (mcg) of the ozone gas (106);

1 ml of the 1% ethanol-water (108); and quantum satis (q.s) HFA134a (108).